NEURAMINIDASE INHIBITORS — THE GOLD STANDARD OF ANTIVIRAL INFLUENZA A THERAPY
https://doi.org/10.21518/2079-701X-2017-4-25-30
Abstract
Influenza is an acute highly contagious respiratory viral infection with a propensity for epidemic spread, affecting all age groups in various geographical conditions. A large number of annually registered cases of severe/complicated course of influenza and deaths are primarily due to the high incidence and involvement in the epidemic process of persons at risk of adverse course of the disease. The main task of the practitioner is to prevent development of severe and complicated forms of influenza that can be achieved at the expense of early diagnosis of influenza and correct evaluation of the condition of the patient given the signs of the progressive course of the disease, and by the timely indication of etiotropic therapy. The antiviral therapy should be indicated within 48 hours from the first symptoms of the disease to all patients with laboratory confirmed diagnosis «flu», as well as to patients with suspected influenza infection with a high risk of complications, regardless of vaccination status against influenza and regardless of the severity of the disease. Seasonal influenza viruses A(H3N2) and A(H1N1)pdm09 currently circulating on the territory of the Russian Federation, are characterized by high sensitivity to neuraminidase inhibitors — oseltamivir and zanamivir, which allows us to recommend these drugs as first-line drugs for the etiotropic therapy of flu.
About the Authors
V. V. TSVETKOV
Scientific and Research Institute of influenza of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
G. S. GOLOBKOV
Scientific and Research Institute of influenza of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Карпова Л.С., Поповцева Н.М., Столярова Т.П., Столяров К.А., Соминина А.А., Бурцева Е.И. Анализ эпидемии гриппа 2016 года и пандемии 2009 года по материалам двух национальных центров ВОЗ в Российской Федерации. Эпидемиология и Вакцинопрофилактика, 2016, 4(89): 4-12.
2. Nicholson KG. Clinical features of influenza. Semin Respir Infect, 1992, 7: 26–37.
3. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med, 2009, 360: 2605-2615.
4. Cowling BJ, Chan KH, Fang VJ et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med, 2010, 362: 2175–2184.
5. Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med, 2010, 362: 1708–1719.
6. Cao B, Li XW, Mao Y et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med, 2009, 361: 2507–2517.
7. Ho YC, Wang JL, Wang JT et al. Prognostic factors for fatal adult influenza pneumonia. J Infect., 2009, 58: 439–445.
8. Schrag SJ, Shay DK, Gershman K et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003–2004. Pediatr Infect Dis J, 2006, 25: 395–400.
9. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med, 2009, 361: 1935–1944.
10. Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA, 2009, 302: 1896–1902.
11. Shieh WJ, Blau DM, Denison AM et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol., 2010, 177: 166–75.
12. Libster R, Bugna J, Coviello S et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med, 2010, 362: 45–55.
13. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA, 2009, 302: 1872–1879.
14. Webb SA, Pettila V, Seppelt I et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med, 2009, 361: 1925–1934.
15. Van Kerkhove MD, Vandemaele KA, Shinde V et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med, 2011, 8(7).
16. Lim B.H., Mahmood T.A. In_uenza A H1N1 2009 (Swine Flu) and Pregnancy. J Obstet Gynaecol India, 2011, 61(4): 386–393.
17. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. WHO. 2010.
18. European Centre for Disease Prevention and Control. Influenza Reporting Protocol 2016. Seasonal influenza. 2016.
19. Hayden F. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza. Annex 5-Considerations for the Use of Antivirals during an Influenza pandemic. Geneva. 2002.
20. FDA. Antiviral Drug Advisory Committee. Gaithersburg: Centre for Drug Evaluation and Research. 2002.
21. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet, 2005, 366: 1175–1181.
22. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005—2006 influenza season in the United States. JAMA, 2006, 295: 891–894.
23. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis, 2007, 196: 249–257.
24. De Clercq E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug. Disc., 2006, 5: 1015-1021.
25. Деева Э.Г. Грипп. На пороге пандемии. Руководство для врачей. Изд. «Геотар - Медиа». 2008. С. 198.
26. Centers for Disease Control and Prevention. CDC issues interim recommendations for the use of influenza antiviral medications in the settingof oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008–09 influenza season. 2008. Available at: http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNump00279. Accessed 28 January 2009.
27. Van der Vries E, Van den Berg B, Schutten M. Fatal oseltamivir resistant influenza virus infection. N Engl J Med, 2008, 359: 1074–1076.
28. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol., 2008, 41: 13-19.
29. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet, 2006, 367: 303–313.
30. Roche. Oseltamivir [package insert]. Nutley N.J.: Roche, 2008. Available at: http://www.rocheusa.com/products/tamiflu/pi.pdf.
31. Dobson J, Whitley RJ, Pocock S, Arnold S Monto. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. The Lancet, 2015, 385(9979): 1729–1737.
32. Murphy KR, Elvindson A, Pauksens K, Stein WJ. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Investig, 2000, 20: 337–349.
33. Muthuri SG, Venkatesan S, Myles PR et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09_related pneumonia: an individual participant data meta_analysis. Influenza Other Respir Viruses, 2016, 10(3): 192–204.
34. Penttinen P, Catchpole M. ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation. Influenza Other Respir Viruses, 2016, 10(3): 152–153.
35. WHO. Analysis of recent scientific information on avian influenza A(H7N9) virus. 2017.
36. WHO. Assessment of risk associated with influenza A(H5N8) virus. 2016.
Review
For citations:
TSVETKOV VV, GOLOBKOV GS. NEURAMINIDASE INHIBITORS — THE GOLD STANDARD OF ANTIVIRAL INFLUENZA A THERAPY. Meditsinskiy sovet = Medical Council. 2017;(4):25-30. (In Russ.) https://doi.org/10.21518/2079-701X-2017-4-25-30
Views:
5679
Email this article 